SUBSCRIBE
SUBSCRIBE
News   Drug Development

Mesoblast Limited Revascor Increases Blood Supply to Damaged Heart Muscle

June 9, 2011 | 
1 min read
Melbourne, June 9, 2011 (ABN Newswire) - Results from Mesoblast Limited's (ASX:MSB) (PINK:MBLTY) cardiovascular clinical trials were featured at the Goldman Sachs 32nd Annual Global Healthcare Conference in California today.
Clinical research Phase II Asia Australia
MORE ON THIS TOPIC
Unhappy young woman feel lonely abandoned in crowd suffer from communication lack. Upset girl struggle with depression or mental disorder. Psychological problem. Flat vector illustration.
Neuropsychiatric disorders
Neuphoria’s Social Anxiety Drug Flunks Late-Stage Trial
October 21, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Illustration showing businessman trying to create his own road
Cancer
Exelixis’ Kinase Blocker Sets ‘New Survival Bar’ in Third-Line Colorectal Cancer, Opening Road to FDA
October 21, 2025
 · 
2 min read
 · 
Tristan Manalac
3D Paper Cut Pair of Lung dotted with yellow tumor bacteria infection spread across on a blue background with no text. Yellow dots as virus infection in the lungs. Vector Illustration.
Lung cancer
Akeso, Summit’s PD-1/VEGF Blocker ‘Firmly’ Beats Expectations With Encouraging Survival Data
October 20, 2025
 · 
2 min read
 · 
Tristan Manalac
Creative collage illustration of financial business. Two businessmen shaking hands for partners agreement. Conceptual illustration of success deal, corporate ethic, connection.
Collaboration
Kite Makes $1.5B+ Cell Therapy Pact With Pregene as Others Pull Back
October 17, 2025
 · 
2 min read
 · 
Tristan Manalac